Related Experiment Videos
Does renal osteodystrophy develop and/or progress during the course of rhGH treatment?
1Division of Nephrology, Children's Hospital and Medical Center, University of Washington, Seattle 98105, USA.
British Journal of Clinical Practice. Supplement
|August 1, 1996
Summary
Recombinant growth hormone (GH) use in children with chronic renal failure (CRF) shows no significant bone disease changes. Continued monitoring for renal osteodystrophy (ROD) and biochemical markers is recommended.
Area of Science:
- Endocrinology
- Pediatrics
- Nephrology
Background:
- Recombinant growth hormone (GH) is increasingly used in non-GH-deficient patients.
- Children with chronic renal failure (CRF) are a growing population receiving GH therapy.
- Potential complications, particularly effects on bone health, require careful evaluation.
Purpose of the Study:
- To assess the impact of GH therapy on bone health in children with CRF.
- To evaluate changes in radiographic osteodystrophy and key biochemical markers.
Main Methods:
- Review of recent studies on GH use in pediatric CRF patients.
- Analysis of radiographic osteodystrophy scores.
- Monitoring of serum calcium, phosphorus, alkaline phosphatase, and parathyroid hormone (PTH) levels.
Main Results:
- No significant differences in radiographic osteodystrophy scores or serum calcium, phosphorus, or PTH levels were observed between GH-treated and untreated groups.
- A transient increase in alkaline phosphatase was noted.
- The effect of renal osteodystrophy (ROD) on growth response remains unreported.
Conclusions:
- GH therapy in children with CRF does not appear to significantly worsen bone disease markers.
- Serial monitoring for ROD via radiographs and biochemical markers (calcium, phosphorus, alkaline phosphatase, PTH) is crucial for children with CRF receiving GH.